摘要
胰高血糖素样肽(GLP-1)用于2型糖尿病的治疗正受到广泛关注。自2005年第1个GLP-1受体激动剂艾塞纳肽(exenatide,Byetta)获FDA批准上市至今,已有6种GLP-1受体激动剂相继获批上市。目前上市的GLP-1受体激动剂的体内半衰期相比于天然GLP-1虽然有所延长,但患者仍需每天注射1~2次,因此需开发更为长效化的GLP-1受体激动剂。2014年,两种新的长效GLP-1受体激动剂阿必鲁肽(albiglutide)和多拉鲁肽(dulaglutide)相继获批上市。本文将对长效GLP-1受体激动剂的研究进展进行综述。
Recently,great attention has been paid to research of glucagon-like peptide-1( GLP-1) used in therapy of type 2 diabetes mellitus. Six GLP-1 receptor agonists have been approved since the first GLP-1 receptor agonist exenatide( Byetta) was approved by FDA in 2005. The half-lives of marketed GLP-1 receptor agonists are longer than natural human GLP-1,but most of them still need to be injected once or twice daily. So the studies of GLP-1 receptor agonists mainly focus on long-acting GLP-1 receptor agonists. Two new long-acting GLP-1 receptor agonists,albiglutide and dulaglutide,were approved in 2014. The research advance of long-acting GLP-1 receptor agonists was reviewed in this paper.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2015年第15期1735-1741,共7页
Chinese Journal of New Drugs